- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04070495
A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin
November 27, 2019 updated by: Kyowa Kirin Co., Ltd.
A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin (A Drug Interaction Study With a CYP3A4/5 Inhibitor or Inducer)
The purpose of this study is to investigate the effects of CYP3A4/5 inhibitor or inducer on the pharmacokinetics of KW-6356 when CYP3A4/5 inhibitor or inducer is orally administered to healthy Japanese men for 7 days.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Tokyo
-
Sumida-ku, Tokyo, Japan
- Medical Co. LTA Sumida Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 44 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Subjects having issued written consent to this study at their own discretion
- Japanese men aged 20 to 44 years at the time of informed consent
- Subjects with BMI ≥18.5 and <25.0 at screening
- Subjects with screening results of; resting pulse rate: 40 to 100 bpm, systolic blood pressure: 90 to 139 mmHg, diastolic blood pressure: 40 to 89 mmHg
Exclusion Criteria:
- Subjects with any current disease requiring treatment
- Subjects having drug allergy or its history
- Subjects having psychiatric disease or its history
- Positive results for any of the following infection-related items examined at screening: hepatitis B surface (HBs) antigen, HBs antibody, hepatitis B core (HBc) antibody, hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antigen/antibody, human T-lymphotropic virus (HTLV)-1 antibody, rapid plasma reagin (PRP) test, or Treponema pallidum (TP) antibody.
- Subjects with clinically significant abnormality detected on 12-lead electrocardiogram (ECG) recorded prior to the first administration of investigational product.
- Subjects categorized as patients listed in the warnings or contraindications section of the package insert of the perpetrator drug.
- Subjects having used any drug (including over-the-counter [OTC] drugs, topical agents, vitamin preparations, health supplements, and Chinese herbal medicines) within 2 weeks prior to the first administration of investigational product.
- Subjects having consumed grapefruit (including any food or beverage containing grapefruit) or any food or beverage containing St John's wort within 1 week prior to the first administration of investigational product.
- Subjects having smoked or used smoking cessation agents (including chewing or eating of nicotine-containing products and application of nicotine patches) within 4 weeks prior to the first administration of investigational product.
- Subjects having received inpatient treatment or surgery within 12 weeks prior to the first administration of investigational product.
- Subjects having participated in a clinical study of a pharmaceutical product or a medical device or any equivalent study and used the investigational product or the unapproved medical device within 4 months prior to the first administration of investigational product.
- Subjects having undergone ≥400 mL of blood collection within 12 weeks prior to the first administration of investigational product or ≥200 mL of blood collection within 4 weeks prior to the first administration of investigational product (for blood donation or clinical trial, etc.) or pheresis donation (plateletpheresis or plasmapheresis donation) within 2 weeks prior to the first administration of investigational product.
- Subjects having issued no consent to adoption of any appropriate contraceptive method during the period from day of admission to 12 weeks after the final administration of the perpetrator drug. The appropriate contraceptive method is defined as sexual abstinence or use of 2 of the following contraceptive devices: condom, oral contraceptives, intrauterine device, and pessary.
- Subjects having received KW-6356 before.
- Other subjects unsuitable for participating in the study in the opinion of the investigator or subinvestigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Clarithromycin
|
A single oral dose will be administered at Day 1 and 15
400mg, oral tablet (2 x 200mg), twice daily (BID), Day 8-28
|
Experimental: Rifampicin
|
A single oral dose will be administered at Day 1 and 15
600mg, oral tablet (4 x 150mg), once daily (QD), Day 8-21
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Geometric mean ratio of the pharmacokinetic parameter (AUC0-t) of KW-6356 in combination with or without a perpetrator drug
Time Frame: Starting just before intake of KW-6356 and continued until 168 or 336 hours after intake of KW-6356.
|
Starting just before intake of KW-6356 and continued until 168 or 336 hours after intake of KW-6356.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Geometric mean ratio of the major pharmacokinetic parameters (Cmax) of KW-6356 in combination with or without a perpetrator drug
Time Frame: Starting just before intake of KW-6356 and continued until 168 or 336 hours after intake of KW-6356.
|
Starting just before intake of KW-6356 and continued until 168 or 336 hours after intake of KW-6356.
|
Geometric mean ratio of the major pharmacokinetic parameters (AUC0-∞) of KW-6356 in combination with or without a perpetrator drug
Time Frame: Starting just before intake of KW-6356 and continued until 168 or 336 hours after intake of KW-6356.
|
Starting just before intake of KW-6356 and continued until 168 or 336 hours after intake of KW-6356.
|
Pharmacokinetic parameters (tmax) of KW-6356
Time Frame: Starting just before intake of KW-6356 and continued until 168 or 336 hours after intake of KW-6356.
|
Starting just before intake of KW-6356 and continued until 168 or 336 hours after intake of KW-6356.
|
Pharmacokinetic parameters (CL/F) of KW-6356
Time Frame: Starting just before intake of KW-6356 and continued until 168 or 336 hours after intake of KW-6356.
|
Starting just before intake of KW-6356 and continued until 168 or 336 hours after intake of KW-6356.
|
Pharmacokinetic parameters (Vz/F) of KW-6356
Time Frame: Starting just before intake of KW-6356 and continued until 168 or 336 hours after intake of KW-6356.
|
Starting just before intake of KW-6356 and continued until 168 or 336 hours after intake of KW-6356.
|
Pharmacokinetic parameters (t1/2) of KW-6356
Time Frame: Starting just before intake of KW-6356 and continued until 168 or 336 hours after intake of KW-6356.
|
Starting just before intake of KW-6356 and continued until 168 or 336 hours after intake of KW-6356.
|
Plasma concentrations of a perpetrator drug
Time Frame: Starting just before intake of a perpetrator drug at Day 8 and continued until 12 or 24 hours after the last dose of a perpetrator drug.
|
Starting just before intake of a perpetrator drug at Day 8 and continued until 12 or 24 hours after the last dose of a perpetrator drug.
|
Incidence of treatment-emergent adverse events
Time Frame: Starting 24 hours before intake of KW-6356 and continued until 14 days after the last dose of a perpetrator drug.
|
Starting 24 hours before intake of KW-6356 and continued until 14 days after the last dose of a perpetrator drug.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 27, 2019
Primary Completion (Actual)
November 19, 2019
Study Completion (Actual)
November 19, 2019
Study Registration Dates
First Submitted
August 26, 2019
First Submitted That Met QC Criteria
August 26, 2019
First Posted (Actual)
August 28, 2019
Study Record Updates
Last Update Posted (Actual)
November 29, 2019
Last Update Submitted That Met QC Criteria
November 27, 2019
Last Verified
November 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Parkinson Disease
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-Bacterial Agents
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Leprostatic Agents
- Protein Synthesis Inhibitors
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 CYP3A Inducers
- Antitubercular Agents
- Antibiotics, Antitubercular
- Cytochrome P-450 CYP2B6 Inducers
- Cytochrome P-450 CYP2C8 Inducers
- Cytochrome P-450 CYP2C19 Inducers
- Cytochrome P-450 CYP2C9 Inducers
- Rifampin
- Clarithromycin
Other Study ID Numbers
- 6356-008
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Neurocrine BiosciencesVoyager TherapeuticsCompletedBrain Diseases | Central Nervous System Diseases | Nervous System Diseases | Parkinson's Disease | Parkinsonian Disorders | Movement Disorders | Neurodegenerative Diseases | Idiopathic Parkinson's Disease | Basal Ganglia DiseaseUnited States
-
Second Affiliated Hospital of Soochow UniversityShanghai Regenelead Therapies Co., Ltd.RecruitingAdvanced Parkinson's DiseaseChina
-
AbbVieRecruitingParkinson's Disease (PD)Germany, Denmark, Spain
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
Hubert FernandezRecruitingParkinson's Disease, IdiopathicUnited States
Clinical Trials on KW-6356
-
Kyowa Kirin Co., Ltd.Completed
-
Kyowa Kirin Co., Ltd.Completed
-
Kyowa Kirin, Inc.CompletedHealthy Male SubjectsUnited States
-
Kyowa Kirin, Inc.CompletedHepatic ImpairmentUnited States
-
Kyowa Kirin Co., Ltd.Completed
-
Kyowa Kirin Co., Ltd.Kyowa Hakko Kirin UK, Ltd.CompletedMultiple Myeloma | Chronic Lymphocytic Leukaemia | B-cell Non-Hodgkin's LymphomaUnited Kingdom
-
Kyowa Kirin Co., Ltd.TerminatedAcute Myelogenous Leukemia (AML)United States
-
Kyowa Kirin Co., Ltd.Kyowa Hakko Kirin Pharma, Inc.Completed
-
Kyowa Kirin Co., Ltd.TerminatedDisseminated Intravascular Coagulation (DIC)Japan